Height after photon craniospinal irradiation in pediatric patients treated for central nervous system embryonal tumors
- 26 July 2020
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 67 (10), e28617
- https://doi.org/10.1002/pbc.28617
Abstract
Background We modeled height after craniospinal irradiation (CSI) in pediatric patients with central nervous system (CNS) embryonal tumors to identify factors that impair stature. Procedure During 1996-2012, 212 pediatric patients (131 male) with CNS embryonal tumors received postoperative CSI: 23.4 Gy (n = 147) or ≥36 Gy (n = 65), similar postirradiation chemotherapy, and were followed for at least 5 years without tumor progression or other event. The group was further characterized by age at CSI and hormone-replacement therapy received. Models were developed to identify factors associated with growth impairment and estimate final height. Results With median follow up of 10.2 years (range 5.0-20.4 years), the mean final height z-scores at 18 years of age, compared to United States standards, were −1.3 for female and −1.5 for male survivors. Younger age at the time of CSI, higher CSI dose, and female sex were associated with height impairment. Factors associated with higher growth rates before 15 years of age were older age at CSI, male sex, CSI dose < 36 Gy, replacement therapy for growth hormone (GH) and central adrenal insufficiency, and white race. Growth after age 15 in male survivors was associated with treatment of gonadotropin deficiency. Linear mixed-effects models were developed using clinical factors to estimate final height, demonstrate the unique growth curve of this cohort, and interactions between clinical variable and radiation dose. Conclusions CSI significantly impaired height at current doses used to treat standard- or high-risk CNS embryonal tumors. Measures to reduce the impact of CSI on height should be sought, with our models serving as benchmarks.Keywords
Funding Information
- American Lebanese Syrian Associated Charities
This publication has 29 references indexed in Scilit:
- Growth Hormone Secretion After Conformal Radiation Therapy in Pediatric Patients With Localized Brain TumorsJournal of Clinical Oncology, 2011
- Adult final height after GH therapy for irradiation-induced GH deficiency in childhood survivors of brain tumors: the Belgian experienceActa Endocrinologica, 2010
- Nutritional problems in children treated for medulloblastoma: Implications for enteral nutrition supportPediatric Blood & Cancer, 2009
- Multi-Institution Prospective Trial of Reduced-Dose Craniospinal Irradiation (23.4 Gy) Followed by Conformal Posterior Fossa (36 Gy) and Primary Site Irradiation (55.8 Gy) and Dose-Intensive Chemotherapy for Average-Risk MedulloblastomaInternational Journal of Radiation Oncology*Biology*Physics, 2008
- Economic, Racial, and Cultural Influences on the Growth and Maturation of ChildrenPediatrics in Review, 2005
- Endocrine outcome in children with medulloblastoma treated with 18 Gy of craniospinal radiation therapyNeuro-Oncology, 2004
- Growth hormone deficiency following radiation therapy of primary brain tumors in childrenJournal of Neurosurgery, 1991
- Long-term endocrine sequelae after surgery, radiotherapy, and chemotherapy in children with medulloblastomaCancer, 1987
- Growth and endocrine function after treatment for medulloblastoma.Archives of Disease in Childhood, 1983
- Medulloblastoma in childhood: Long-term results of treatmentCancer, 1981